11 results about "Chagas disease" patented technology

The embodiment of the invention discloses an angiotensin II-1 type receptor polypeptide or a fusion compound and application of the angiotensin II-1 type receptor polypeptide or the fusion compound. The invention provides an angiotensin type 1 receptor polypeptide or fusion, which is coated in a solid phase material (porous plate, magnetic beads, agarose particles, latex particles and the like) and is used for detecting an antibody aiming at an angiotensin II-1 receptor in the body of a patient suffering from diseases such as eclampsia and the like. The compound can also be used for blocking the combination of autoantibodies in the bodies of pregnant women and angiotensin II-1 type receptors, and treating various cardiovascular diseases such as dilated cardiomyopathy, just-gauge disease, heart failure and the like.

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) an antiparasitic agent.

The present disclosure provides novel antigenic peptides and peptide mixtures, and methods of use for the detection of T. cruzi antibodies in tissue samples and the diagnosis of Chagas disease in a subject.

The presently disclosed subject matter provides a method and pharmaceutical composition for long-term use in treating or preventing disease conditions caused by the parasite Trypanosoma cruzi known as Chagas disease. The pharmaceutical composition is a long-term injectable composition that can include a dose of Itraconazole and a dose of Amiodarone in an amount effective to treat Chagas disease, or in an amount effective to prevent Chagas disease in a human or animal patient such as a mammal. The pharmaceutical composition may also include a pharmaceutically acceptable vehicle, carrier, or excipient. The form of itraconazole used in the pharmaceutical composition may be prepared by any suitable process wherein the active ingredients to have sufficient bioavailability when injected into a human or animal subject. The long-term method for treating or preventing Chagas disease is carried out by a single injection of Itraconazole and Amiodarone in an amount effective to treat a subject in need thereof, and / or in an amount effective to prevent the subject from contracting the disease so that repeated dosages are not required again for a long-term period such as 6 or 12 months. The present compositions, methods, and uses are safer and longer lasting, more patient friendly, and provide a safer and more effective way of treating or preventing Chagas disease than previously possible.

Diagnostic methods, systems, test strips, test kits, and other immunoassay materials are provided for the detection of antibodies to one or more specific parasites of veterinary and human concern in biological samples, including those that are responsible for Chagas disease (Trypanosoma cruzi), Leishmaniasis (Leishmania infantum), and Heartworm (Dirofilaria immitis).

The application relates to fumaric acid cocrystals of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazol-5-carboxamide (Compound I) and X-ray amorphous complexes of Compound (I) and fumaric acid. The application also provides methods for their preparation; pharmaceutical compositions containing them; and their use in the treatment, prevention, inhibition, improvement, or eradication of the pathology and / or symptoms of a disease caused by a kinetoplastid parasite, such as leishmaniasis, human African trypanosomiasis, and Chagas disease.

Provided herein are methods, systems, microplates, compositions, and kits for detecting the presence or recent presence of an infection caused by an infectious disease in a subject. In some embodiments, the infectious disease is Lyme disease, hepatitis, Chagas disease, or a human immunodeficiency virus infection.

The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

The invention provides a modified Trypanosoma cruzi Tc24 polypeptide comprising an amino acid substitution at one or more of amino acid positions: 23, 98, 141, or any combination thereof, relative to the parent Trypanosoma cruzi Tc24 polypeptide. The invention further provides a diagnostic test comprising the modified Trypanosoma cruzi Tc24 polypeptide and a method of diagnosing an individual with Chagas disease using the diagnostic test of claim.

T, cruzi antigens that are useful for detection infection are provided. Methods of detection and various assay formats are also provided.